Latest Industry Insights
Industry Insight
Drug Candidate for Lung Cancer Receives FDA Fast Track Designation
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Industry Insight
A New Generation of Recombinant Monoclonal Antibodies
Technology Networks spoke with Isaku Tanida, Head of Protein and Pathway Technologies, Life Science at Merck to learn about Merck's ZooMAb® recombinant antibodies. These antibodies are developed from a B-cell immortalization technology which enables production in a variety of species.
Industry Insight
Developing the Next Generation of Drugs for Dermatological Conditions
We recently spoke with Robb Knie, CEO of Hoth Therapeutics to learn more about the company’s mission, drug development pipeline, and the various dermatological conditions they are designing therapeutics for.
Industry Insight
Rethinking Chemical Synthesis With Cell-free Biocatalysis
Technology Networks recently had the pleasure of speaking with Debut Bio's CEO Dr Joshua Britton. We discuss the evolution of chemical manufacturing, key challenges faced by those working in the field, and the benefits of combining biocatalysis and continuous manufacturing.
Industry Insight
Data from Direct-to-Consumer Genetic Tests Used To Create a Drug for Inflammatory Diseases
At the beginning of the year, direct-to-consumer (DTC) genetic testing company 23andMe announced that they have generated a bispecific antibody that blocks the IL-36 cytokine family associated with multiple inflammatory diseases. Technology Networks spoke with Christine Pai from 23andMe to find out more.
Industry Insight
Facilitating Cell Culture Growth and Protecting Protein Integrity
Many biotherapeutic drugs such as recombinant antibodies are manufactured utilizing host cells, a common example being Chinese hamster ovary (CHO) cells. A key factor for consideration in this process is the growth and viability of these cells – ultimately this influences the quality and quantity of the biotherapeutic product. Technology Networks spoke with Nicole Wellens, Global Product Manager for BioTherapeutics Media, Lonza to learn more about the new feed and how it has been developed.
Industry Insight
Delving Into Glycogen Storage Diseases
In this interview, Gaia Fancellu, of Iceni Diagnostics, talks about her work in more detail, discusses the challenges of studying GSDs, and highlights the advantages of using a “Systems Medicine” approach to do so.
Industry Insight
Releasing the Handbrake on Endogenous Repair – An Alternative Approach to Treating Alzheimer’s Disease?
Technology Networks recently spoke with Paul Brennan, President and CEO at NervGen Pharma, to gain his insights on why previous attempts to treat Alzheimer's disease have failed, how the novel technology platform NVG-291 works and what promise it holds for AD.
Industry Insight
Ensuring Reliable Material Identification in Pharmaceutical Manufacturing
Variability in the quality of raw materials can not only impact production yields, but can also affect the quality, efficacy and safety of the final pharmaceutical product. In this interview, learn about how the capabilities of two handheld analyzers ensure reliable material identity verification.
Industry Insight
Center Set To Support the Delivery of Novel, High-quality Therapeutics
We recently spoke with Thermo Fisher Scientific's Eric Grumbach, to learn more about the opening of the company's new Pharma and BioPharma Center, located in Shanghai, China. The center is set to support the rapid delivery of novel and high-quality therapeutics by providing expertise in critical analytical techniques and specialized workflows.
Advertisement